XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Código da empresaXOMA
Nome da EmpresaXoma Royalty Corp
Data de listagemJun 06, 1986
CEOMr. Owen P. Hughes, Jr.
Número de funcionários13
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 06
Endereço2200 Powell Street
CidadeEMERYVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94608
Telefone15102047200
Sitehttps://xoma.com/
Código da empresaXOMA
Data de listagemJun 06, 1986
CEOMr. Owen P. Hughes, Jr.
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados